Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Dabigatran and rivaroxaban are non-vitamin K oral anticoagulants approved for stroke prevention in patients with nonvalvular atrial fibrillation (AF). There are no randomized head-to-head comparisons of these drugs for stroke, bleeding, or mortality outcomes.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JAMA Intern Med

Title: JAMA internal medicine

Publisher: American Medical Association (AMA)

ISSN (Electronic): 2168-6114

ISSN (Print): 2168-6106

Publication date (Electronic): Nov 01 2016

Volume: 176

Issue: 11

Affiliations

[1 ] Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

[2 ] Acumen LLC, Burlingame, California.

[3 ] Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

[4 ] Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

[5 ] Acumen LLC, Burlingame, California5Department of Economics, Stanford University, Stanford, California.

[6 ] Centers for Medicare & Medicaid Services, Washington, DC.

Article

Publisher Item ID: 2560376

DOI: 10.1001/jamainternmed.2016.5954

PubMed ID: 27695821

SO-VID: 690e4f20-1f70-4925-8cba-458e5bfe8b16

History

Data availability:

Comments

Comment on this article

scite_

Cited by 96

See all cited by

- Version 1